Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 11, 2023
Initiated IDE161 Phase 1 expansion based on preliminary tumor shrinkage observed in multiple HRD solid tumor patients, including an endometrial cancer subject with a first imaging assessment of a...
-
Sep 5, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...
-
Aug 21, 2023
GSK101 (IDE705) is being developed as a potential first-in-class Pol Theta Helicase Inhibitor in combination with niraparib in GSK-sponsored Phase 1/2 clinical trial GSK101 and niraparib...
-
Aug 16, 2023
Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) Preliminary clinical activity...
-
Aug 10, 2023
Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 Initiated Phase 2/3 registrational trial for...
-
Aug 2, 2023
- First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase 1/2 clinical trial - Global...
-
Aug 1, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming...
-
Jul 28, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 27, 2023, the...
-
Jun 30, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 29, 2023, the...
-
Jun 22, 2023
Eye preservation reported for the first UM patient treated with darovasertib monotherapy under the amended IST protocol enabling neoadjuvant treatment up to 6 months Patient experience shared in...
-
Jun 12, 2023
Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancers Observed partial response by RECIST 1.1...
-
May 30, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...
-
May 26, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 25, 2023, the...
-
May 22, 2023
IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid tumors Potential first-in-class synthetic lethality combination...
-
May 16, 2023
Amended clinical trial collaboration and supply agreements with Pfizer to support evaluation of IDEAYA's planned Phase 2/3 registrational clinical trial to evaluate Daro + Crizo in 1L MUM...
-
May 9, 2023
Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by $188.7 million estimated net proceeds from closing of underwritten...
-
May 1, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...
-
Apr 28, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 27, 2023, the...
-
Apr 27, 2023
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 8,858,121 shares of its common stock at a public offering price of $18.50 per share,...
-
Apr 24, 2023
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,439,201 shares of common stock...
-
Apr 24, 2023
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $150 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA...
-
Apr 23, 2023
Confirmed overall response rate (ORR) of 45%, disease control rate (DCR) of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patients Based on FDA meeting, initiating Phase 2/3...
-
Apr 19, 2023
- Evaluating IDE161 in patients having solid tumors with HRD, with expansion focus in ER+ / Her2- breast cancer with HRD, representing approximately 10% to 14% of breast cancer - Dose escalation...
-
Apr 3, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...
-
Mar 31, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 30, 2023, the...